HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nanoparticles Exacerbate Both Ubiquitin and Heat Shock Protein Expressions in Spinal Cord Injury: Neuroprotective Effects of the Proteasome Inhibitor Carfilzomib and the Antioxidant Compound H-290/51.

Abstract
Increased levels of ubiquitin and heat shock protein (HSP) 72 kD are often seen in spinal cord injury (SCI). However, their roles in cell injury or survival are not well known. Thus, we have investigated the possible relationship between ubiquitin and HSP expressions in relation to cell injury in healthy animals, or following nanoparticle (NP) intoxication in SCI animals. A focal SCI was inflicted on the T10-11 segments over the right dorsal horn; animals were allowed to survive from 5 to 8 h after trauma. Separate groups of rats were exposed to SiO2, Ag, or Cu NPs for 7 days and subjected to SCI on the eighth day. A marked increase in ubiquitin or HSP immunoreactive cells occurred in the T9 to T12 segments 5 h after the injury, which further extended to the T4 and L5 after 8 h of survival. At this time, a marked increase in blood-spinal cord barrier (BSCB) permeability to Evans blue and radioiodine, accompanied by an intense edema formation, was observed. Changes were further exacerbated in NP-treated traumatized rats. The most marked expressions of ubiquitin and HSP in SCI were seen in rats treated with SiO2, followed by Ag, and Cu NPs. Treatment with H-290/51 (50 mg/kg p.o., 30 to 60 min after injury) or carfilzomib (1 mg/kg, i.v., 30 to 60 min after trauma) significantly reduced the ubiquitin or HSP expressions, as well as the BSCB breakdown, the edema formation, and the cell injury in the cord both 5 and 8 h after the injury, in normal animals. However, a double dose of H-290/51 (100 mg/kg) or carfilzomib (2 mg/kg) is needed to reduce cord pathology or ubiquitin and HSP expressions in traumatized animals treated with NPs. H-290/51 showed superior beneficial effects in reducing cord pathology in SCI than carfilzomib. These observations are the first to demonstrate that (i) NP-treated traumatized animals induce a widespread BSCB leakage, edema formation, and cord pathology as well as an overexpression of ubiquitin and HSP, (ii) high doses of antioxidant compounds or proteasome inhibitors are required for neuroprotection in the NP-exposed traumatized group, and (iii) ubiquitin and HSP expressions play a key role in neuronal injury in SCI, not reported earlier.
AuthorsHari S Sharma, Dafin F Muresanu, Jose V Lafuente, Per-Ove Sjöquist, Ranjana Patnaik, Aruna Sharma
JournalMolecular neurobiology (Mol Neurobiol) Vol. 52 Issue 2 Pg. 882-98 (Oct 2015) ISSN: 1559-1182 [Electronic] United States
PMID26126513 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Antioxidants
  • H290-51
  • HSP72 Heat-Shock Proteins
  • Indoles
  • Nerve Tissue Proteins
  • Neuroprotective Agents
  • Oligopeptides
  • Proteasome Inhibitors
  • Ubiquitin
  • Silver
  • carfilzomib
  • Silicon Dioxide
  • Copper
Topics
  • Animals
  • Antioxidants (pharmacology, therapeutic use)
  • Copper (administration & dosage, toxicity)
  • Drug Evaluation, Preclinical
  • Edema (etiology, prevention & control)
  • HSP72 Heat-Shock Proteins (biosynthesis, genetics)
  • Indoles (pharmacology, therapeutic use)
  • Male
  • Nanoparticles (toxicity)
  • Nerve Tissue Proteins (biosynthesis, genetics)
  • Neuroprotective Agents (pharmacology, therapeutic use)
  • Oligopeptides (pharmacology, therapeutic use)
  • Proteasome Inhibitors (pharmacology, therapeutic use)
  • Rats
  • Rats, Wistar
  • Silicon Dioxide (administration & dosage, toxicity)
  • Silver (administration & dosage, toxicity)
  • Spinal Cord (metabolism, pathology)
  • Spinal Cord Injuries (complications, drug therapy, etiology, metabolism)
  • Thoracic Vertebrae
  • Ubiquitin (biosynthesis, genetics)
  • Up-Regulation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: